AXDX Accelerate Diagnostics Inc
Price (delayed)
$0.7
Market cap
$17.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.15
Enterprise value
$69.13M
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC
Highlights
Accelerate Diagnostics's EPS has soared by 56% YoY and by 19% from the previous quarter
The company's net income rose by 19% YoY and by 6% QoQ
The gross margin rose by 9% YoY but it fell by 4.9% QoQ
The gross profit has decreased by 6% QoQ but it has increased by 6% YoY
AXDX's equity has shrunk by 182% YoY and by 16% QoQ
AXDX's debt has soared by 70% YoY and by 13% QoQ
Key stats
What are the main financial stats of AXDX
Market
Valuations
Earnings
Shares outstanding
25.21M
Market cap
$17.65M
Enterprise value
$69.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
Revenue
$11.7M
Gross profit
$2.7M
Operating income
-$35.31M
Net income
-$50.05M
EBIT
-$36.99M
EBITDA
-$33.57M
Free cash flow
-$24.7M
Per share
Balance sheet
Liquidity
EPS
-$2.15
EPS diluted
-$2.15
Free cash flow per share
-$1.06
Book value per share
-$2.24
Revenue per share
$0.5
TBVPS
$1.23
Total assets
$28.56M
Total liabilities
$84.6M
Debt
$66.58M
Equity
-$56.04M
Working capital
-$8.96M
Debt to equity
-1.19
Current ratio
0.71
Quick ratio
0.59
Net debt/EBITDA
-1.53
Margins
Efficiency
Dividend
EBITDA margin
-287%
Gross margin
23.1%
Net margin
-427.8%
Operating margin
-301.8%
Return on assets
-174.9%
Return on equity
N/A
Return on invested capital
-79.6%
Return on capital employed
N/A
Return on sales
-316.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXDX stock price
How has the Accelerate Diagnostics stock price performed over time
Intraday
-0.86%
1 week
-20.19%
1 month
-35.19%
1 year
-25.55%
YTD
-41.67%
QTD
-0.14%
Financial performance
How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$11.7M
Gross profit
$2.7M
Operating income
-$35.31M
Net income
-$50.05M
Gross margin
23.1%
Net margin
-427.8%
The operating income has increased by 35% year-on-year and by 7% since the previous quarter
Accelerate Diagnostics's operating margin has increased by 33% YoY and by 6% from the previous quarter
The company's net income rose by 19% YoY and by 6% QoQ
AXDX's net margin is up by 16% YoY and by 4.7% QoQ
Growth
What is Accelerate Diagnostics's growth rate over time
Valuation
What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
Accelerate Diagnostics's EPS has soared by 56% YoY and by 19% from the previous quarter
AXDX's equity has shrunk by 182% YoY and by 16% QoQ
AXDX's price to sales (P/S) is 93% less than its 5-year quarterly average of 19.8 and 41% less than its last 4 quarters average of 2.4
The revenue has declined by 3% year-on-year
Efficiency
How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's return on invested capital has surged by 63% YoY and by 13% QoQ
Accelerate Diagnostics's ROS has increased by 28% YoY and by 11% from the previous quarter
Accelerate Diagnostics's ROA has decreased by 22% YoY but it has increased by 4.1% from the previous quarter
Dividends
What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXDX.
Financial health
How did Accelerate Diagnostics financials performed over time
The company's total assets is 66% lower than its total liabilities
The company's current ratio has shrunk by 65% YoY and by 53% QoQ
Accelerate Diagnostics's total liabilities has soared by 65% YoY and by 4.7% from the previous quarter
AXDX's equity has shrunk by 182% YoY and by 16% QoQ
AXDX's debt has soared by 70% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.